Etesevimab

A4DAB112 | Approved

Target SARS-CoV-2 Spike RBD

Isotype / Subclass G1 / None

Company

Eli Lilly and Company Institute of Microbiology of the Chinese Academy of Sciences Shanghai Junshi Biosciences

Clinical Status Approved

Format Whole mAb

Synonyms

JS 016 JS-016 JS016 JS16 JS-16 JS 16 LY 3832479 LY-3832479 LY3832479 LY-CoV-016

pH Formulation —

IMGT PubChem (434321766) PubChem (434370465) PubChem (442064771) PubChem (472422390) PubChem (476262681) PubChem (476269283) PubChem (481155452) PubChem (483929053) Thera-SAbDab YAbS

Avg A4D Score

-0.6483

Score Range

-0.67 to -0.63

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB112_7c01_C_D	7c01	100%	-0.6297	6.5	4.0	-0.1226	-0.6929
A4DAB112_7c01_H_L	7c01	100%	-0.667	6.5	4.0	-0.1147	-0.7358

Etesevimab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2